VivArt-X develops synthetic support material for specific cell therapies. Our lead indication will revolutionize breast reconstructive surgery in women who have undergone breast tissue removal after breast cancer diagnosis. Approximately 50% of the 2.3 million breast cancer patients worldwide need cancerous tissue removal and require breast reconstructive surgery. The estimated global market of breast reconstructive surgery is 2.7 billion in 2021, with a CAGR of 10%.
Current breast reconstruction methods make use of toxic silicone implants, infection-prone autologous flap surgery or fat grafting. Unfortunately, these autologous reconstruction methods are not optimal, which results in long intensive surgeries, volume reduction and (multiple) intensive complications.
VivArt-X offers a revolutionary synthetic, degradable support material as a personalized breast reconstruction method with ultimately tissue regeneration.
The support material is based on synthetic components that can be tuned to the requirements of a specific cell type with respect to the mechanical and biological properties. To show clinical validation of our first product we need an investment of 8M Euro. We are finalizing our feasibility studies. To start the development fase, we need a first investment of at least 500K Euro.
The team of VivArt-X combines expertise in biomedical engineering and chemistry and has excellent experience with business development. Prof. Dankers has a track record in developing support materials to culture various single cell types, complex cell aggregates and organoids, a.o. derived from induced pluripotent stem cells. She is also the co-founder of the company UPyTher. Dr. ir. Dan Jing Wu has a scientific and engineering background with entrepreneurship experience.
Last updated: July 2022